Trousseau so correctly observed is presented next, followed by a discussion of the thrombotic mechanisms of anticancer drugs, and prevention and treatment guidelines.
DIAGNOSTIC CLUES TO CANCER-RELATED THROMBOSIS
In interpreting Trousseau's quotations above, some have named his syndrome "phlebitis migrans," which implies migratory superficial thrombophlebitis. Perhaps "multifocal" superficial thrombophlebitis is a better term. Whether it is multifocal or not, when it occurs without apparent cause in unusual locations, it may be associated with cancer (3) . Clinicians, thinking of "phlebitis migrans," associate bilateral deep vein thrombosis with cancer, but until recently there were no prospective studies to support that concept.
Two reports, one retrospective and another prospective, support the concept that there is a strong association between bilateral thrombosis and malignancy (4, 5) . In certain cancers local invasion or compression of arteries or veins will cause thrombosis. Attention is thus drawn to the possibility of cancer in locations such as the mediastinum, the nasal sinuses, the eye, or the abdomen in the region of the inferior vena cava. Primary or metastatic lesions of the clavicle may cause jugular vein thrombosis or stroke due to carotid artery thrombosis. Edema of any part of the body may occur as a result of stasis induced by compression of a vein, whether associated with thrombosis of that vein or not.
"Changes in the blood," as suggested by Trousseau in 1865 (see above) as well as by Virchow in 1866 (6) , have in recent years been confirmed by the laboratory tests that detect the effects of thrombin on the blood, depending on the degree to which the cancer primarily or secondarily activates the coagulation system. Many of these effects are procoagulant mediated and difficult to assay in a clinical laboratory. Global coagulation test results such as the prothrombin time and activated partial thromboplastin time, the thrombin time, assays of fibrinogen, fibrinogen split products, and d-dimer (the degradation product of cross-linked fibrin) may be abnormal and reflect the aberrant systemic action of thrombin in cancer patients. Additional sensitive markers of intravascular coagulation are low levels of antithrombin and the presence of the fragments of prothrombin cleavage (fragment 1.2) and thrombin-antithrombin complexes. Tests for these abnormalities are usually found in reference laboratories. Less commonly, products of extreme systemic fibrinolysis with very low fibrinogen levels along with low levels of plasminogen and its inhibitors are found, such as in acute promyelocytic leukemia or prostate cancer.
In hereditary venous hypercoagulable disorders, the most common defects are found in the system of proteins that form the natural inhibitors of coagulation, such as antithrombin, tissue factor pathway inhibitor, and the protein C system. In cancer, the concentrations and functionality of these inhibitors of coagulation may be altered by various mechanisms and also play a role in cancer-associated thrombosis. (7) A hypercoagulable state occurring as a result of cancer may lead to thrombosis with little evidence of consumption coagulopathy (occult or nonovert disseminated intravascular coagulation (8, 9) .
PRIMARY MECHANISMS OF THROMBOSIS IN CANCER
The pathogenesis of thrombosis in malignancy is complex and not yet completely understood. A hypercoagulable state occurs through several interdependent processes between the cancer cells and the patient (10) . Tumor cells can directly activate the clotting cascade through the release of procoagulant molecules. They also indirectly activate the same clotting cascades by the release of inflammatory cytokines (11) . The inflammatory response often propagates the prothrombotic state by stimulating the release of more procoagulant molecules from the tumor cells. Breakdown in the vascular endothelium and activation of leukocytes and platelets additionally lead to blood clot formation (12) .
Tumor cells can express surface markers and release soluble factors that are capable of activating blood coagulation. Three such molecules are tissue factor, cancer procoagulant, and hepsin (13) .Tissue factor (TF) is the most studied and best understood of the cancer cell procoagulants. The TF molecule is a 47 kDa transmembrane protein receptor that acts as the principal surface receptor and cofactor for activated protease factor VIIa (FVIIa). The extrinsic coagulation pathway is triggered when TF binds to FVIIa and thrombin generation ensues. TF also plays a role in intracellular signaling involved with tumor growth and the metastatic potential of certain cancers (11) . Aberrant TF expression has been detected in a variety of human tumors, including glioma, breast cancer, non-small cell lung cancer, leukemia, colon cancer, and pancreatic cancer (14) . It has not been found on corresponding normal tissue. Overexpression of TF occurs at late stages of disease progression (15) . Until recently, the mechanism of TF overexpression in cancer cells was unknown. TF is a target of specific genetic alterations. Two of the more common, inactivation of p53 and mutation of K-ras, appear to be cumulative in human colorectal cancer (CRC) (16) . A cell line genetically engineered to accumulate these alterations in a stepwise fashion was found to up-regulate TF in a cooperative manner. This suggests that TF upregulation and hypercoagulability in patients with malignancy may have a genetic component.
Two other factors, the protease hepsin and cancer procoagulant (CP) are also known to enhance thrombotic activity of tumor cells. CP is a cysteine protease with coagulation factor X (FX) as its only known physiological substrate. The conversion of FX to FXa occurs independently of FVIIa (12) . Cancer procoagulant has been found in several human malignancies including melanoma, neuroblastoma, sarcoma, non-small cell lung cancer, breast cancer, colon cancer, renal cell carcinoma, and acute leukemias (17, 18) . Unlike TF, CP is found almost exclusively on malignant cells, and is elevated in the serum of approximately 85% of cancer patients (19) . CP has been evaluated as a tumor marker in several malignancies. Overall, this has not been consistently reproduced except in acute promyelocytic leukemia (APL). The APL subtype has the highest level of CP expression of all the acute leukemias. The CP activity also parallels the course of the disease. When patients achieve a remission they do not express CP in the bone marrow cells. CP activity can be detected before the reappearance of malignant cells in patients with relapse of their disease (20) .
Hepsin is a type II transmembrane serine protease physiologically expressed in high levels in liver tissue. It is also found in other tissues including kidney, pancreas, lung, thyroid, pituitary gland, and testis. Hepsin is overexpressed in several tumors, specifically ovarian and prostate carcinomas (21) . Hepsin activates FVIIa independent of TF, resulting in thrombin formation. It can also catalyze low levels of FXa and thrombin in the absence of FVII.
Tumor cells produce cytokines, which promote coagulation and suppress anticoagulant activity (12) . Specifically, tumor necrosis factor (TNF) and interleukin-1 (IL-1) induce expression of TF on vascular endothelial cells (VEC). They also downregulate the surface receptor thrombomodulin on VEC, which lowers the generation of activated protein C. Normally, thrombomodulin binds thrombin and activates the protein C system. Activated protein C functions as a naturally occurring anticoagulant. Thus an increased level of TF combined with decreased activated protein C activity forms an environment on the endothelium prone to thrombosis (22) .
Interleukin-8 (IL-8) is a cytokine originally classified as a neutrophil chemoattractant that plays an important role in disease progression and metastatic potential of tumor cells. It is produced by several cell types including endothelial cells, monocytes, fibroblasts, and neutrophils. While it has been extensively studied in lung cancer, IL-8 expression occurs in many cancers types (23) . It plays a role in angiogenesis, tumor progression, cell survival, and alterations in immune response by directly interacting with both tumor cells and their microenvironment. Elevated concentrations of IL-8 have even been associated with venous thrombosis in the absence of cancer (24) .There are several proposed mechanisms to explain this association. IL-8 production stimulates an increase in TF. It also acts as a chemoattractant for neutrophils. Neutrophils adhere to VEC and promote thrombus formation. IL-8 is also known to trigger the adhesion of monocytes to VEC, which may lead to a procoagulant surface on which a thrombus can form (25) .
In addition to IL-8, other cytokines stimulate endothelial cells to produce tissue-type plasminogen activator inhibitor (PAI-1). The breakdown of blood clots (fibrinolysis) is regulated by a balance between t-PA activators and their inhibitors. PAI-I expression suppresses the fibrinolytic system, resulting in unrestrained coagulation activation (25, 26) . This imblalance in fibrinolytic activity has been seen in patients with solid tumors, specifically gastric cancer, resulting in increased risk of venous thromboembolism (27, 28) .
Patients respond to the presence of tumor with the release of both cytokines and procoagulant molecules when mounting an inflammatory response. This results in the activation of macrophages and stimulation of T-cells, further promoting the release of TNF and IL-1 into the milieu. These cytokines consequently promote a prothrombotic environment (11) . Furthermore, tumor-associated macrophages increase their expression of TF. VEC upregulate the expression of leukocyte and cellular adhesion molecules, as well release increased amounts of platelet-activating factor. The inflammatory response induced by tumor cells has been recreated in animal models, and mimicked in in vitro studies. A direct link between many of these individual mechanisms and thrombosis in patients with cancer has not been demonstrated. For example, simple infusion of TNF leads to an increase in markers of coagulation, but rarely results in clinical thrombosis (26, 29) . It is more likely the combined effects of several alterations in multiple pathways that lead to thrombosis. Selectin-mucin interactions as a probable molecular explanation for the association of Trousseau syndrome with mucinous adenocarcinomas have been proposed (27) . Until the mechanisms are further elucidated, caution should be taken in interpreting the experimental data.
It has been increasingly recognized that the tumor microenvironment talks to and coevolves with the primary cancer. A specialized stroma evolves with the cancer. This is distinguished by unique modifications in the nonepithelial cell types that secrete extracellular matrix (ECM) proteins and growth factors. Research into the so-called "cross-talk" of this specialized stroma and the primary cancer is in its infancy. In addition to contributing to cancer progression, this interaction will likely be shown to contribute to the thrombotic tendency of cancer. There is already evidence that the direct interaction between tumor cells and host cells is a key mechanism in thrombosis formation. This occurs via direct cell-cell interaction, as well as the indirect mechanisms previously discussed. Activated macrophages/monocytes are increased in the circulation of patients with different malignancies. They are found to be at higher concentration in close proximity to growing tumors (27, 29) . The tumor-associated macrophages directly activate the coagulation cascade through factor XII and factor X. They also release cytokines, including IL-1, TNF, and IL-6, inducing the sloughing of endothelial cells and converting the vascular lining over which blood flows to a thrombogenic surface.
Platelets have also been suggested to play a role in the development of secondary metastasis as well as thrombosis in malignancy (30) . Adhesion receptors on tumor cells bind and directly activate platelets. The release of cytokines and metabolites from the tumor cells indirectly activate platelets. The tumor and vessel walls interact via GPIIB/IIIA integrin expression (31) .
Several factors extrinsic to the tumor itself contribute to the prothrombotic state. These include direct vessel trauma from central venous catheters, venous stasis from restricted mobility or compression of vessels from tumor bulk, and cancer therapy (32) .
DIAGNOSTIC IMAGING
Proof of the presence or absence of venous or arterial thrombosis by physical examination alone can be unreliable unless the circumstantial evidence is very strong. Ultrasonographic imaging is the method of choice for diagnosing proximal leg vein thrombosis. It is less reliable for distal or lower leg thrombosis and not at all for pelvic vein thrombosis (33, 34) . Contrast venography is the method of choice for distal leg vein and pelvic vein thrombosis. Magnetic resonance imaging (MRI) is now becoming available for detection of abdominal vein thrombosis (35, 36) . Computed tomography (CT) scanning utilizing special techniques with contrast may also be used for pelvic veins.
THERAPY-INDUCED THROMBOSIS IN CANCER (INCLUDING RADIATION THERAPY)
Various drugs used in the management of cancer carry the risk of thrombosis. The responsible agents belong to many different groups and act through a host of mechanisms. The major drug groups associated with increased risk of thrombosis include chemotherapeutic agents, hormones, antibody-toxin conjugates, agents that cause thrombotic thrombocytopenic purpura (TTP), and miscellaneous drugs such as thalidomide, antiangiogenic agents, heparin, and erythropoietin (see Table 3 ).
Chemotherapeutic Agents
The largest experience about the risk of thrombosis with systemic therapy has been in breast cancer. The risk appears to increase during treatment and returns to baseline afterward. Data obtained from 10 large studies were reviewed by Prandoni in 1997 (37) . In total, 6844 patients, treated between 1981 and 1996, were included in the analysis. They had stage II to IV disease and were treated with a variety of therapeutic regimens, the most frequent of which were CMF (cyclophospahamide, methotrexate, and 5-fluorouracil) and CAF (cyclophosphamide, doxorubicin, and 5-fluorouracil). Both arterial and venous thromboses were seen and the risk varied from 2% to 15%. In the three largest studies with 1014, 1292, and 2352 patients, respectively, the risk was 1.3%, 2%, and 5%, respectively. The risk for thrombosis appeared to increase if the patients also received tamoxifen. Perioperative chemotherapy increases the incidence of thrombosis when compared to surgery alone (2.1% versus 0.6%) (38) . Different chemotherapy regimens do not appear to affect the risk of thrombosis, at least in the adjuvant setting (39) .
The cause(s) of thrombosis during chemotherapy remain(s) unclear. The proposed mechanisms include endothelial injury, impaired vitamin K metabolism, direct platelet activation, reduced fibrinolytic activity, and release of procoagulant materials from the dying tumor cells. The proof for any of these mechanisms is scanty. Rogers et al reported a fall in proteins C and S with CMF chemotherapy (40) . But others (41) were unable to confirm these findings, even though an occasional low protein C level was noted. D-dimer, fibrinogen, and AT-III levels have been reported to be normal during chemotherapy.
L-asparaginase
Administration of L-asparaginase in patients with acute lymphoblastic leukemia (ALL) has been associated with venous thromboembolism. Intracranial dural sinus thrombosis, deep venous thrombosis, and pulmonary emboli have all been reported, with an overall risk of about 1.2% in children. L-asparaginase inhibits protein synthesis by depleting asparagine, which is responsible for its antileukemic effect. But it also interferes with synthesis of many proteins, such as albumin; prothrombin; factors V, VII, VIII, IX, X, XI; fibrinogen; AT-III; proteins C and S; and plasminogen. Since both procoagulant and anticoagulant proteins are affected by L-asparaginase, it becomes difficult to predict how the hemostatic balance would be affected. In the clinical setting, however, the most easily recognizable laboratory effects are the prolongation of prothrombin time (PT), partial thromboplastin time (PTT), and hypofibrinogenemia. These abnormalities persist for 1-2 weeks after discontinuation of therapy.
The available data suggest that administration of antithrombin (AT-III) during L-asparaginase therapy may prevent thromboembolic complications. In a recent single-institution retrospective study reported by Elliot et al (42) , the incidence of thrombosis in adult patients undergoing induction therapy for ALL was 18.5% (10 of 54). Median baseline AT-III levels were 94% and fell to 47% during therapy. Seventeen patients (of 54) received prophylactic AT-III concentrate replacement and ten did not. None of the patients who received prophylactic AT-III concentrates developed venous thromboembolism (VTE) (p=0.021), all the thromboses occurring in the control group. Another study-an open-label, randomized, controlled trial in which children undergoing ALL induction chemotherapy received AT-III replacement or no AT-III replacement-has also addressed this issue (43) . It was not powered to define efficacy or safety of AT-III replacement but was able to demonstrate a trend for efficacy of AT-III replacement in children. Interestingly, 28% of patients in the AT replacement arm had a thromboembolic complication compared to 37% in the no AT-III replacement arm. The efficacy of AT-III replacement is an area that warrants further investigation.
It appears that L-asparaginase may affect the cleavage of von Willebrand factor (vWF), resulting in transient increase in unusually large plasma vWF multimers. These have significant platelet-aggregating property and may contribute to the thrombotic risk (44) . The Erwinia form of L-asparaginase is associated with fewer and less severe coagulopathy.
Other Chemotherapeutic Agents
Anecdotal experience has linked other chemotherapeutic agents to the development of thromboembolism. Dacarabazine, either alone or in combination, has been associated with development of hepatic vein thrombosis (Budd-Chiari syndrome). Venoocclusive disease of the liver has been reported with the use of thioguanine plus daunorubicin. Bleomycin, cisplatin, and vinblastine have been associated with development of myocardial infarction and stroke. 5-Fluorouracil (5-FU), given as continuous infusion, may be associated with a significant risk of myocardial infarction and stroke. The myocardial infarction with 5-FU infusion may be the result of coronary spasm.
Hormones/Hormone-chemotherapy Conjugates
Estrogens increase the plasma levels of coagulation factors and have been long known to increase the risk of thrombotic complications. Diethylstilbestrol (DES), once a popular therapy for carcinoma of the prostate, is rarely used now. Estramustine, an estradiol-chemotherapy conju-gate, is sometimes used in the management of prostate cancer. The most common indication of hormonal therapy at present is breast cancer. The main agents in use are tamoxifen and aromatase inhibitors.
Tamoxifen
Clinical experience with the use of tamoxifen is extensive. A number of large studies, including the Breast Cancer Prevention Trials, show that tamoxifen increases the risk of venous thromboembolism. When it is combined with chemotherapy, the incidence of this complication goes up significantly (45) (46) (47) (48) (49) . The combined data from 13 NSABP breast cancer prevention trials, which included 20,878 patients, show that use of tamoxifen was associated with twofold to threefold increase in the risk of deep venous thrombosis, pulmonary embolism, and superficial phlebitis. If tamoxifen was combined with chemotherapy, the risk escalated 11-to 15-fold. Older age and increased body mass index, but not race, were found to be adverse prognostic factors (50) . In the placebo-controlled International Breast Cancer Intervention Study involving 7139 patients, use of tamoxifen increased the incidence of venous thromboembolism twofold. This risk was further increased by surgery, immobilization, or fractures (49) .
Presence of factor V Leiden and prothrombin gene mutation does not appear to be associated with increased risk of thromboembolism with tamoxifen. Whether tamoxifen increases the incidence of stroke is still debatable. The possibility was raised by data from P-1 and NASB-24 trials, but retrospective data on 11,045 women in another study did not support those findings (51) . A meta-analysis of controlled trials published since 1980 has shown that, at a median followup of 4.9 years, the risk of stroke was 0.71% with tamoxifen and 0.39% in controls (52) . It appears that the risk of stroke in these patients is small and is increased with use of tamoxifen.
The mechanism by which tamoxifen increases the risk of thrombosis is not known. Some reports suggest that antithrombin and protein C levels may be reduced with tamoxifen use, but other studies do not confirm these findings.
Newer Hormonal Agents
Aromatase inhibitors, which are being used with increased frequency in breast cancer, have been reported to have a <2% risk of thrombosis. These include deep venous thrombosis, pulmonary emboli, portal vein thrombosis and stroke. Megace also increases the risk of thrombosis, which approaches 6%.
Should breast cancer patients receiving chemotherapy or hormonal treatments be treated with anticoagulation? There are minimal data in patients with metastatic disease who are given chemotherapy. In one prospective study of 311 patients with metastatic disease, the subjects received either placebo or warfarin at a dose of 1 mg daily. The international normalized ratio (INR) in the warfarin group was between 1.3 and 1.9. After six months, there were seven thromboembolic events in the placebo group and one in the warfarin group (53) . Bleeding risk was not increased.
Estramustine
Estramustine, an estradiol molecule linked to nitrogen mustard, was synthesized in the mid-1960s as an alkylating agent specifically for the treatment of advanced prostate carcinoma. The estradiol portion was designed to facilitate uptake by steroid receptors on malignant cells, thereby augmenting the intracellular release of the nitrogen mustard. Docetaxel and estramustine have been used in combination for the treatment of hormone-refractory prostate cancer. A phase 2 trial of this combination in metastatic prostate cancer showed a 9% risk of DVT (54) . A subsequent phase 3 trial comparing docetaxel/ estramustine to mitoxantrone and prednisone showed that the two regimens were equivalent in efficacy but the mitoxantrone arm was less toxic. The rate of thromboembolism was not different in the two arms. Since then, estramustine has been used only infrequently in the management of prostate cancer (55) . Another study has shown that the addition of warfarin to docetaxel plus estramustine eliminates the risk of venous thromboembolism (56) .
Thrombotic Microangiopathy and Chemotherapy
Thrombotic microangiopathy has been described in patients with cancer with the development of disseminated intravascular coagulation (DIC) and with the administration of certain drugs. The thrombotic microangiopathy seen with drugs resembles hemolytic uremic syndrome (HUS) rather than thrombotic thrombocytopenia purpura (TTP). The drugs most commonly implicated in the development of this syndrome are cyclosporine, mitomycin, and cisplatin. Gemcitabine and the combination of cisplatin plus bleomycin have also been reported to be associated with the development of HUS/TTP (57) (58) (59) (60) . The HUS/TTP associated with cyclosporine has been principally limited to patients with renal allografts. Mitomycin C-associated HUS/TTP typically occurs 4 to 8 weeks after exposure to mitomycin C but has been reported to occur as late as 6 months after exposure to the drug. The most common symptoms at presentation are dyspnea, pulmonary edema, and acute respiratory distress syndrome (ARDS). Progressive renal failure is universal. There appears to be a correlation with the cumulative dose of mitomycin C, and the occurrence of TTP-HUS tends to occur with a total dose of greater then 40 mg. The exact incidence of TTP-HUS attributable to mitomycin C has been difficult to establish because TTP-HUS has also been described in patients with metastatic cancer.
The mechanism of thrombotic angiopathy due to drugs remains controversial. In one study, five of the six patients had abnormalities of von Willebrand factor multimers (61), but another report (62) showed no such changes in patients with mitomycin-associated microangiopathy. In all cases, however, endothelial injury appears to play a major role.
The prognosis appears to be grim in these patients, and it is not clear if plasma exchange has any influence on the final outcome.
Miscellaneous Agents
Miscellaneous agents include thalidomide, anti-VEGF agents, gemtuzumab-ozogomicin, heparin, erythropoietin, COX-2 inhibitors, and catheter-related thrombosis.
Thalidomide
Thalidomide has become an important agent in the treatment of multiple myeloma and is also being studied in a variety of other malignancies. Clinical trials with thalidomide have shown impressive response rates in patients with multiple myeloma but also an increased risk of deep vein thrombosis. Multiple myeloma itself increases the risk of thromboembolism by a variety of mechanisms. The incidence of deep venous thrombosis (DVT) in patients with multiple myeloma treated with thalidomide alone appears to be small, at about 1% (63) . The combination of thalidomide and chemotherapy, however, increases this risk dramatically. In a study of 169 patients with previously untreated multiple myeloma, Zangari and colleagues (64) observed a 28% incidence of DVT in patients treated with combination chemotherapy (DCEP) plus thalidomide 400 mg daily as compared to 4% in the chemotherapy alone arm. The median time to diagnosis of DVT was 42.5 days, and all DVTS occurred during the first three cycles of therapy. The combination of doxorubicin and thalidomide also appears to be quite thrombogenic. Another report by Zangali et al, which included patients treated with thalidomide plus combination chemotherapy with or without doxorubicin, showed a 16% incidence of VTE in the doxorubicin group compared to 2.5% in the non-doxorubicin control arm (p=0.02) (65) . There was no correlation between VTE and response rates. Although the mechanism of thalidomide+chemotherapy-associated thrombosis is still under investigation, a number of early observations have been reported. These include acquired activated protein C resistance in the absence of factor V Leiden gene mutation, elevated factor VIII and VWF: Ag, antithrombin III deficiency; proteins C and S deficiency; elevated homocysteine levels; and higher VEGF levels (66) (67) (68) .
Bevacizumab
Bevacizumab is an anti-vascular endothelial growth factor (VEGF) antibody, which has been tried in a variety of malignancies. Its use has been associated with both venous and arterial thrombosis. Twelve of 67 (17.9%) patients receiving 5 or 10 mg/kg bevacizumab plus 5-fluorouracil and leucovorin had a thrombotic event (69) . The exact mechanism is not clear, but aggravation of hypertension may play a role.
Gemtuzumab Ozogomicin
Gemtuzamb-ozogomicin (Mylotarg ® ) is a useful agent in the management of acute myeloid leukemia. It has been reported to cause DIC-like syndrome in about 2% of the patients, which may be associated with thrombotic complications. It also causes venoocclusive disease (VOD) of the liver, which may be in part due to thrombosis. The risk of VOD increases, especially when the drug is given within a short duration preceding allogeneic stem cell transplantation (70, 71) . VOD of the liver is a clinical syndrome characterized by hyperbilirubinemia, painful hepatomegaly, and fluid retention. VOD is most commonly seen in patients undergoing hematopoietic stem cell transplantation. The etiology is thought to be cytokine activation and alteration in coagulation proteins in response to tissue injury. The end result is the microvascular obstruction of the terminal venules in the liver. VOD has been associated with virtually every transplant preparative regimen. Optimal therapy for VOD of the liver is still under investigation, but prophylaxis with a variety of agents like heparin, tissue plasminogen activator, prostaglandin E1, ursodeoxycholic acid, and pentoxifylline has been tried with varying degree of success. Therapy with antithrombin III concentrates and defibrotide is still under investigation but may be useful (72) .
Heparin
Heparin-induced thrombocytopenia (HIT) and thrombosis (HITT) is a feared and often a catastrophic complication of a drug widely used in the practice of oncology. Heparin can cause an acute thrombocytopenia, usually within 24 hours of starting it, but this is a nonimmune-mediated event, which is not associated with platelet activation or thrombosis. It reverses promptly with cessation of heparin. The second form of heparin-induced thrombocytopenia occurs via an IgG antibody directed against the heparin plus platelet factor 4 (PF4). It usually occurs five to 21 days after the beginning of heparin therapy (the interval may be shorter in patients with previous exposure to heparin), results in platelet activation, and is associated with thrombosis. The incidence of heparin-induced thrombocytopenia has varied widely in the literature. Based on the prospective data, its incidence varies from 1% to 5% (73) . The risk of thrombosis after development of HIT is about 29% (74) . Incidence of heparin-induced thrombocytopenia with low-molecular-weight heparin is lower (75) . Heparin-induced thrombocytopenia should be suspected when the platelet counts declines by 50% from the baseline or when absolute thrombocytopenia occurs in a patient on heparin therapy. Both venous and arterial thrombi may occur, resulting in deep venous thrombosis, pulmonary emboli, limb ischemia, native coronary arterial thrombosis, coronary bypass graft occlusion, or stroke. Laboratory studies for diagnosis of heparin-induced platelet antibodies include heparin-induced platelet aggregation assays and the serotonin release assay. Prompt recognition and avoidance of any further heparin exposure is the mainstay of therapy. If necessary, non-cross-reacting direct thrombin inhibitors such as lepirudin or argatroban should be used.
Erythropoietin
Erythropoietin and its long-acting form darbepoetin are widely used for the treatment of anemia in patients with both hematologic and solid malignancies. About 6.2% of patients develop thrombotic complications during the use of these two agents, primarily affecting patients whose hemoglobin level has become higher than 12 g/dL (hematocrit of 36% or higher). A rapid rise in hemoglobin, i.e., greater than 1 g/dL during any two weeks of therapy also appears to increase the risk of complications, which include superficial and deep vein thrombosis, pulmonary embolism, angina, and thrombosis of vascular access sites (76) .
Cyclooxygenase-2 (COX-2) Inhibitors
COX-2 inhibitors have been widely used as antiinflammatory agents and may have a role as chemopreventive drugs for many epithelial cancers. However, these agents have also been recently found to increase the risk of cardiovascular events such as myocardial infarction, stroke, and pulmonary emboli. COX-2 is the main source of systemic prostacyclin, which is an inhibitor of platelet aggregation and smooth muscle proliferation. Prostacyclin also is a vasodilator. Thus COX-2 inhibitors create a prothrombotic state. Three large clinical studies (77) (78) (79) , including 2035, 1671, and 2586 patients, respectively, show that the risk of cardiovascular events is increased 2-3 times. Two of the three studies were colorectal adenoma prevention trials.
Catheter-related Thrombosis
A significant proportion of cancer patients have an indwelling central venous catheter. These remain in place for weeks and months, sometimes for years. Within days of insertion, the venous catheters become coated with a fibrin sheath. Clinically evident thrombi form within a month. Despite routine flushing, about 40% of the patients (range 3% to 62%) develop catheterrelated thrombosis (80) . This risk changes with the type of catheter used, the underlying malignancy, and the therapy received by the patient. Inherited thrombophilic conditions do not appear to increase the risk. About one third of the catheter-related thrombi are symptomatic, about half of which result in pulmonary emboli. Postphlebitic syndrome can result from a catheter-related thrombosis. The prophylactic treatment to reduce the risk of catheter-related thrombosis remains controversial. Low-molecular-weight heparins do not appear to help. The data regarding the use of low-dose warfarin is conflicting, with some studies showing a benefit while others do not.
PROPHYLAXIS OF DEEP VEIN THROMBOSIS IN CANCER PATIENTS
The prophylaxis of deep vein thrombosis in cancer patients is essentially the same as for noncancer patients having the same risk factors exclusive of cancer. The exceptions are primarily in surgical patients who are raised to a higher level of risk, prompting the use of pharmacologic measures in addition to physical measures. For instance, patients with abdominal cancer or advanced-stage metastatic cancer would receive pharmacologic prophylaxis even if they are under age 40 and ambulatory provided the bleeding risk is not excessive. Postoperative pharmacologic prophylaxis would be continued for 10-35 days depending on the risk (81) . The use of warfarin to maintain patency of intravenous catheters is no longer recommended (81) . Medical cancer patients are managed basically the same as other medical patients in terms of prophylaxis of venous thromboembolism (81) . Prophylaxis of arterial and venous thrombosis in patients receiving drug therapy for cancer has not been studied except for one prospective trial consisting of 311 patients with metastatic breast cancer receiving chemotherapy randomized to low-dose warfarin vs placebo. The frequency of symptomatic venous thromboembolism was reduced from 4.5% to 0.8%. The international normalized ratio (INR) was maintained between 1.3 and 1.9 (82) .
TREATMENT (SECONDARY PROPHYLAXIS) OF THROMBOEMBOLISM
Thrombosis in cancer patients is treated essentially the same as it is in patients without cancer. It has long been known that some cancer patients with deep vein thrombosis experience recurrent thrombosis while adequately anticoagulated. This is relatively uncommon and unexplained, but such patients must be maintained on subcutaneous adjusted-dose unfractionated heparin or low-molecular-weight heparin indefinitely. The duration of therapy in patients who are not refractory is dependent on the persistence of risk. Otherwise, therapy lasts usually for six months in the absence of residual cancer or other persistent risk (83) .
Low-molecular-weight heparin (LMWH) efficacy in warfarin-refractory patients has not been specifically shown in a dedicated study. One study demonstrated LMWH to be more effective and as safe as warfarin (84) . The CLOT trial, a prospective randomized trial comparing the two drugs for six months in 336 patients who had cancer and proximal deep vein thrombosis, demonstrated an equal risk of bleeding and no survival benefit at six months (85) . Another trial using LMWH for secondary prophylaxis of deep vein thrombosis in patients with cancer compared enoxaparin with warfarin in a three-month trial. There was a trend to decreased recurrence of venous thromboembolism with less bleeding with the LMWH (85) . The use of LMWH in this setting has been limited by concerns of increased cost. This difference is felt to be offset by a decreased need for lab monitoring, and a reduction in recurrence of thromboembolism (86, 87) . Extended LMWH, specifically with dalteparin, represents an alternative to oral anticoagulation. This was endorsed in the most recent practice guidelines of the American College of Chest Physicians (ACCP) (87) .
Heparin-induced thrombocytopenia and/or thrombosis in patients with cancer receiving heparin should be be treated initially with the nonheparin anticoagulants lepirudin or argatroban, or danaparoid, a heparinoid ( not available in the United States) (88) .
Newer Drugs
Tissue factor inhibitors or factor Xa inhibitors, currently in the early stages of development, may find a place in the management of cancer-related thrombosis. Fondaparinux, a pure factor Xa inhibitor, is a synthetic heparin-like drug that is approved for prophylaxis of deep vein thrombosis in hip replacement surgery. This drug may prove useful in cancer surgery patients as well as in cancer-associated thromboembolic disorders (89) . A rationale for the development of specific inhibitors of tissue factor has been proposed and such drugs may be forthcoming (90) .
